
Mylan issues recall for anxiety drug Xanax over contamination fears
pharmafile | October 29, 2019 | News story | Manufacturing and Production | Mylan, anxiety, pharma, xanax
Mylan has announced it has issued a recall of its anxiety therapy Xanax (alprazolam) over suspicions the drug could be contaminated with a “foreign substance” and pose a risk to patients.
The alert was made known via the FDA website and concerns the 0.5mg tablet formulation of the drug, made available throughout July and August this year in bottles of 500.
“Clinical impact from the foreign material, if present, is expected to be rare, but the remote risk of infection to a patient cannot be ruled out,” said Mylan in the notice. “To date, Mylan has not received any adverse events related to this batch.”
The drugmaker contacted wholesalers and retailers with instructions to return the affected product; consumers were also contacted in turn with similar instructions. Xanax is typically used for the management of anxiety disorder, and can provide relief for panic disorder.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …






